Document Detail


Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: An analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial.
MedLine Citation:
PMID:  24016495     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
AIMS: In the EARLY ACS trial, routine early eptifibatide was not superior to delayed provisional use at percutaneous coronary intervention (PCI); however, among PCI-treated patients, numerically fewer ischemic end points occurred in the upstream eptifibatide group. We sought to further explore this finding using methods for examination of treatment effect in this postrandomization subgroup.
METHODS AND RESULTS: Of 9,406 patients in the EARLY ACS primary analysis cohort, 9,166 (97.4%) underwent coronary angiography. We used Cox proportional hazards regression modeling, with PCI as a time-dependent covariate, to examine the effect of routine early versus delayed provisional eptifibatide among 5,541 patients undergoing PCI and to explore the interaction between treatment with PCI and randomized treatment strategy. After multivariable adjustment, compared with delayed provisional use, routine early eptifibatide was associated with lower rate of 30-day death or myocardial infarction (MI) after PCI (hazard ratio [HR] 0.80, 95% CI 0.68-0.95) but not with medical management (HR 0.97, 95% CI 0.74-1.29); PCI × randomized treatment interaction term P = .24. Excluding PCI-related MI, the adjusted HR for 30-day death or MI for routine early eptifibatide versus delayed provisional use was 0.80 (95% CI 0.60-1.08) for post-PCI treatment and 1.01 (95% CI 0.79-1.34) for medical management; PCI × randomized treatment interaction term P = .28.
CONCLUSIONS: Consistent with previous literature, upstream treatment with eptifibatide was associated with improved outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients treated with PCI; however, a nonsignificant interaction term precludes a definite conclusion.
Authors:
Akshay Bagai; Jennifer A White; Yuliya Lokhnygina; Robert P Giugliano; Frans Van de Werf; Gilles Montalescot; Paul W Armstrong; Pierluigi Tricoci; C Michael Gibson; Robert M Califf; Robert A Harrington; L Kristin Newby
Related Documents :
23463975 - Prehospital treatment of st-segment elevated myocardial infarction patients.
24070595 - Management of pericarditis and myocarditis: could heart-rate-reducing drugs hold a prom...
6616575 - Ultrastructural morphometry of the myocardium of thunnus alalunga.
8534905 - Spatial organization of cardiac gap junctions can affect access resistance.
1814055 - Acute respiratory distress syndrome--two decades later.
6370525 - Fetal cardiac structure and function as studied by ultrasound.
Publication Detail:
Type:  Journal Article     Date:  2013-07-25
Journal Detail:
Title:  American heart journal     Volume:  166     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2013 Sep 
Date Detail:
Created Date:  2013-09-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  466-473.e1     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2013 Mosby, Inc. All rights reserved.
Affiliation:
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A prospective regional registry of ST-elevation myocardial infarction in Central Romania: Impact of ...
Next Document:  Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: In...